Keverprazan
Phase 3Small molecule
Keverprazan is one of 25 small molecule programs targeting Upper Gastrointestinal Bleeding. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Helicobacter Pylori Eradication
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Potassium Citrate
MMission Pharmacal
Approved
Levaquin
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Minocin
TTriax
Approved
Furoxone
UUniversity of New Hampshire
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori2 trials
Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori
Not yet recruiting·KKey Laboratory for Gastrointestinal Diseases of Gansu Province·N/A·NCT06851468·264 enrolled
Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori
Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT06412640·268 enrolled
Helicobacter Pylori Eradication1 trial
The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication
Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 1·NCT06777732·672 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Keverprazan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details